The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksScancell Holdings Regulatory News (SCLP)

Share Price Information for Scancell Holdings (SCLP)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 10.10
Bid: 9.70
Ask: 10.50
Change: 0.00 (0.00%)
Spread: 0.80 (8.247%)
Open: 10.10
High: 10.10
Low: 10.10
Prev. Close: 10.10
SCLP Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

10 Sep 2012 11:10

RNS Number : 8777L
Scancell Holdings Plc
10 September 2012
 



 

 

 

TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi

1. Identity of the issuer or the underlying issuerof existing shares to which voting rights areattached: ii

Scancell Holdings plc

2 Reason for the notification (please tick the appropriate box or boxes):

An acquisition or disposal of voting rights

X

An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached

An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments

An event changing the breakdown of voting rights

Other (please specify):

3. Full name of person(s) subject to thenotification obligation: iii

Calculus Capital Limited

4. Full name of shareholder(s)  (if different from 3.):iv

HSBC Global Custody (UK) Limited

5. Date of the transaction and date onwhich the threshold is crossed orreached: v

7 September 2012

6. Date on which issuer notified:

10 September 2012

7. Threshold(s) that is/are crossed orreached: vi, vii

11%

 

8. Notified details:

A: Voting rights attached to shares viii, ix

Class/type ofshares

if possible usingthe ISIN CODE

Situation previousto the triggeringtransaction

Resulting situation after the triggering transaction

NumberofShares

NumberofVotingRights

Numberof shares

Number of votingrights

% of voting rights x

Direct

Direct xi

Indirect xii

Direct

Indirect

Ordinary Shares

ISIN: GB00B39J5N63

23,189,770

23,189,770

21,339,770

21,339,770

10.97%

B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

Type of financialinstrument

Expirationdate xiii

Exercise/Conversion Period xiv

Number of votingrights that may beacquired if theinstrument isexercised/ converted.

% of votingrights

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi

Resulting situation after the triggering transaction

Type of financialinstrument

Exercise price

Expiration date xvii

Exercise/Conversion period xviii

Number of voting rights instrument refers to

 

% of voting rights xix, xx

 

 

 

Nominal

Delta

Total (A+B+C)

Number of voting rights

Percentage of voting rights

21,339,770

10.97%

 

9. Chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held, if applicable: xxi

 

N/A

Proxy Voting:

10. Name of the proxy holder:

N/A

11. Number of voting rights proxy holder will ceaseto hold:

N/A

12. Date on which proxy holder will cease to holdvoting rights:

N/A

13. Additional information:

N/A

14. Contact name:

Calculus Capital Limited

15. Contact telephone number:

0207 493 4940

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLLLFIIADIILIF
Date   Source Headline
20th Nov 20197:00 amRNSNew European Moditope patent allowed for grant
23rd Oct 20197:00 amRNSDirectorate Change
26th Sep 20197:00 amRNSPosters at Cancer Immunotherapy Conference
12th Sep 20193:56 pmRNSResult of AGM
4th Sep 20197:00 amRNSFirst Collaboration Agreement for AvidiMab
20th Aug 20192:23 pmRNSNotice of AGM
20th Aug 20197:00 amRNSFinal Results for the year ended 30 April 2019
19th Aug 20197:00 amRNSUpdate on the SCIB1 Phase 2 clinical trial
7th Aug 20197:00 amRNSNotice of Final Results
1st Jul 20197:00 amRNSH1 2019 Business Update
18th Jun 20199:16 amRNSHolding(s) in Company
18th Jun 20197:00 amRNSBoard Appointment
17th Jun 201910:45 amRNSHolding(s) in Company
14th Jun 20194:41 pmRNSSecond Price Monitoring Extn
14th Jun 20194:35 pmRNSPrice Monitoring Extension
13th Jun 20197:00 amRNSShare Subscription and Issue of Equity to Vulpes
29th May 201911:05 amRNSSecond Price Monitoring Extn
29th May 201911:00 amRNSPrice Monitoring Extension
20th May 20197:00 amRNSScancell and CRUK provide an update on SCIB2
10th May 20197:00 amRNSClinical Advisory Board and Update on Modi-1
25th Apr 20197:00 amRNSUK approval to start SCIB1 Phase 2 trial
8th Apr 20197:00 amRNSJapan patent for Moditope immunotherapy platform
21st Mar 20197:00 amRNSProfessor Lindy Durrant receives Waldenström award
20th Mar 20197:00 amRNSScancell strengthens IP portfolio
5th Mar 20196:27 pmRNSHolding(s) in Company
4th Mar 20194:40 pmRNSSecond Price Monitoring Extn
4th Mar 20194:35 pmRNSPrice Monitoring Extension
21st Feb 20197:00 amRNSChange of Auditor
31st Jan 20197:00 amRNSInterim Results
23rd Jan 20197:00 amRNSUpdate on Cancer Research UK's Grand Challenge
21st Jan 20197:00 amRNSAppoints Heads of Research and Manufacturing
12th Nov 20187:00 amRNSScancell to Present at Two Conferences
1st Nov 20187:00 amRNSScancell to present at Proactive Investors Forum
30th Oct 20185:18 pmRNSResults of AGM
30th Oct 20187:00 amRNSIdentification of 2nd Moditope Cancer Vaccine
24th Oct 20189:05 amRNSSecond Price Monitoring Extn
24th Oct 20189:00 amRNSPrice Monitoring Extension
24th Oct 20187:00 amRNSUpdate on SCIB1 Phase 2 Clinical Study
5th Oct 20187:00 amRNSNotice of AGM
25th Sep 20187:00 amRNSFinal Results for the year ended 30 April 2018
18th Sep 20187:00 amRNSNotice of Final Results
10th Aug 20187:00 amRNSBoard Change
9th Aug 20187:00 amRNSAgreement
25th Jul 20182:45 pmRNSDirector/PDMR Shareholding
24th Jul 20187:00 amRNSIssue of Equity
18th Jul 20187:00 amRNSScancell exercises TriGrid commercial option
23rd May 20187:00 amRNSGrant of European patent for Moditope platform
11th May 20181:11 pmRNSHolding(s) in Company
9th May 201810:12 amRNSHolding(s) in Company
8th May 20187:00 amRNSResult of the Open Offer and PDMR Shareholdings

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.